СУЧАСНІ РЕКОМЕНДАЦІЇ ЩОДО ЛІКУВАННЯ МІСЦЕВО-ПОШИРЕНОГО РАКУ МОЛОЧНОЇ ЗАЛОЗИ (ОГЛЯД ЛІТЕРАТУРИ)

R.V. Seniutovych; V.P. Unguryan; S.Yu. Kravchuk; I.O. Malyshevsky; V.V. Shulgina; L.Y. Kushneryk; J.Ya. Chuprovska

doi:10.24061/2413-0737.XXI.3.83.2017.109

Автор(и)

R.V. Seniutovych
V.P. Unguryan
S.Yu. Kravchuk
I.O. Malyshevsky
V.V. Shulgina
L.Y. Kushneryk
J.Ya. Chuprovska

DOI:

https://doi.org/10.24061/2413-0737.XXI.3.83.2017.109

Ключові слова:

місцево-поширений рак молочної залози, неоад’ювантна хіміотерапія

Анотація

Мета роботи – провести метааналіз статей та рефератів ста- тей на сайті Pebmed за останні п’ять років щодо комплексного лікування місцево-поширеного раку молочної залози. У даній статті представлені сучасні рекомендації щодо спеціаль- ного лікування місцево-поширеного раку молочної залози, вказані недоліки та переваги різних лікувальних тактик, підкреслені неви- рішені питання. Висновок. На сьогоднішній день потребує подальшого розробки та вдосконалення алгоритму лікувальної тактики місцево- поширеного раку молочної залози, особливо питання об’єктивної оцінки ступеня регресії пухлини після неоад’ювантної хіміотера- пії, застосування сторожової лімфаденектомії до початку останньої.

Посилання

Cancer Care Ontario (cco), Breast Cancer Disease Site Group. Breast Irradiation in Women with Early Stage Invasive Breast Cancer Following Breast Conserving Surgery Toronto, ON: CCO; 2002. Evidence-based series 1-2. Ver. 2. I. Clin. Oncol. 2003;4:194 - 214.

Deo SV, Bhutani M, Shukla NK. Randomized trial comparing neoadjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). J. Surg. Oncol. 2003;84:192–7.

Hage JA, Velde CJ,, Julien JP. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J. Clin. Oncol. 2001;19:4224–37.

Wolmark N, Wang J, Mamounas E. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001:96 – 102.

Brackstone M, Fletcher GG, Dayes I. Locoregional Therapy of Locally Advanced Breast Cancer (LABC) Toronto, September 29, 2014. Cancer Care Ontario. 2014;11:121- 141.

Boileau JF, Simmons C, Clemons M. Extending neoadjuvant care through multi-disciplinary collaboration: proceedings from the Fourth Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer. Curr Oncol. 2012;19:106–14.

Macdonald SM, Haffty BG, Harris EE. Оn behalf of the Expert Panel on Radiation Oncology-Breast, American College of Radiology(acr) ACR Appropriateness Criteria: Locally Advanced Breast Cancer. Reston, VA: ACR, 2011:529-36.

Musat E, Poortmans P, Van den Bogaert W. Quality assurance in breast cancer: eortc experiences in the phase iii trial on irradiation of the internal mammary nodes. Eur. J. Cancer. 2007;43:718–24.

Schwartz GF, Hortabagyi GN. Cancer. Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast. Breast Cancer. April 26-28, 2003:2512–32.

Dawood S, Merajver SD, Viens P. International Expert Panel on Inflammatory Breast Cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22:515–23.

Clarke M, Collins R, Darby S. On behalf of the Early Breast Cancer Trialists' Collaborative Group Effects of radiotherapy and of differences in the extent of surgery for Scientific reviews early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.

McGale P, Kammers K, Boelke E. The 2006 worldwide overview of the effects of local treatments for early breast cancer on long-term outcome. Int. J. Radiat. Oncol. Biol. Phys. 2006;66:2–3.

Budach W. Adjuvant radiotherapy of regional lymph nodes in breast cancer-a meta-analysis of randomized trials. Radiat Oncol. 2013;8:267-9.

McGale P, Taylor C, Correa C. On behalf of the Early Breast Cancer Trialists' Collaborative Group Effect of radiotherapy after mastectomy and axillary surgery on 10- year recurrence and 20-year breast cancer mortality: metaanalysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.

Nes van JG, Putter H, Julien JP. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the eortc trial 10902. Breast. Cancer. Res. Treat. 2009;115:101–13.

Whelan TJ, Julian J, Wright J.Does locoregional radiation therapy improve survival in breast cancer? A metaanalysis. J. Clin. Oncol. 2000;18:1220–9.

Schmoor C, Bastert G, Dunst J. Randomized trial on the effect of radiotherapy in addition to 6 cycles cmf in nodepositive breast-cancer patients. The German BreastCancer Study Group. Int. J. Cancer. 2000;86:408–11.

Rutqvist LE, Johansson H. Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among "high risk" pre- and postmenopausal breast cancer patients. Acta Oncol. 2006;45:517–27.

Matzinger O, Heimsoth I, Poortmans P. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage i to iii breast cancer (eortc trial 22922/10925). Acta Oncol. 2010;49:24–34.

Minckwitz von G, Kummel S, Vogel P. On behalf of the German Breast Group Neoadjuvant vinorelbinecapecitabine versus docetaxel-doxorubicincyclophosphamide in early nonresponsive breast cancer: phase iii randomized GeparTrio trial. J. Natl. Cancer. Inst. 2008;100:542–51.

Poortmans P, Fourquet A, Collette L. Irradiation of the internal mammary and medial supraclavicular lymph node chain in stage i to i breast cancer: state of the day of eortc phase iii trial 22922/10925 with 4004 patients. Breast Cancer. 2010;8:54.

Horst KC, Haffty BG, Harris EE. On behalf of the Expert Panel on Radiation Oncology-Breast, American College of Radiology(acr) ACR Appropriateness Criteria: Postmastectomy Radiotherapy. Reston, VA: ACR. 2012:235- 42.

Krag D, Weaver D, Ashikaga T. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med. 1998;339:941–6.

Fowble BL, Einck JP, Kim DN. On behalf of the Athena Breast Health Network Role of postmastectomy radiation after neoadjuvant chemotherapy in stage ii-iii breast cancer. Int J Radiat Oncol Biol Phys. 2012;83:494–503.

Boughey JC, Suman VJ, Mittendorf EA. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients. Ann Surg. 2014;17:27-31.

Boughey JC, Suman VJ, Mittendorf EA. On behalf of the Alliance for Clinical Trials in Oncology Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the acosog Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.

Lucci A, McCall LM, Beitsch PD. On behalf of the American College of Surgeons Oncology Group Surgical complications associated with sentinel lymph node dissection (slnd) plus axillary lymph node dissection compared with slnd alone in the American College of Surgeons Oncology Group Trial Z0011. J. Clin. Oncol. 2007;25:3657–63.

Papa MZ, Zippel D, Kaufman B. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J. Surg. Oncol. 2008;98:403–6.

Vazquez Guerrero A, Flipo B, Namer M. Benefits of sentinel lymph node biopsy before neoadyuvant chemotherapy in T2-T3 N0 patients-Cercle Sainte Agathe. Eur. J. Surg. Oncol. 2010;36:809.

Kuehn T, Bauerfeind I, Fehm T. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (sentina): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609 –18.

Bear HD, Anderson S, Smith RE. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol. 2006;24:2019–27.

Mamounas EP, Anderson SJ, Dignam JJ. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J. Clin. Oncol. 2012;30:3960-6.

Rastogi P, Anderson SJ, Bear HD. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J. Clin. Oncol. 2008;26:778–85.

Qi M, Li JF, Xie YT. Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer. Breast Cancer Res Treat. 2010;123:197–202.

Senjutovych RV, Gonca AO, Ungurjan VP. Aktual'ni pytannja organozberigajuchogo likuvannja raku molochnoi' zalozy. Chernivci: Prut. 2010.275s.

Senjutovych RV, Ahtemijchuk NT, Ungurjan VP. Miscevoposhyrenyj rak molochnoi' zalozy. Hirurgichni ta anatomichni aspekty. Chernivci: Misto. 2003.129s.

Senjutovych RV. Neoad’juvantna elektrohimioterapija miscevo-poshyrenogo raku grudnoi' zalozy. Chernivci: Misto. 2003.129s.

Senjutovych RV, Bizer LI, Ushenko OG. Neoad’juvantna himioterapija raku molochnoi' zalozy. Faktory prognozu. Chernivci: Prut. 2010.162s.